OptimizeRx Cuts 2026 Revenue Guidance to $109–114M After Q4 Beat
OptimizeRx reported Q4 earnings of $0.51 per share versus $0.23 consensus, with revenues rising to $32.2 million and adjusted EBITDA of $12 million. The company reduced fiscal 2026 revenue guidance to $109–114 million (from $118–124 million) and projects adjusted EBITDA of $21–25 million, citing Most Favored Nation pricing uncertainty.
1. Strong Fourth-Quarter Performance
OptimizeRx delivered Q4 earnings of $0.51 per share, more than double the $0.23 consensus, on revenue of $32.2 million and adjusted EBITDA of $12.0 million, reflecting robust network engagement and operational leverage.
2. Fiscal 2026 Guidance Revision
The company trimmed its fiscal 2026 revenue outlook to $109–114 million from $118–124 million and now expects adjusted EBITDA of $21–25 million, citing cautious customer spending patterns.
3. MFN Pricing and Market Volatility
Management highlighted uncertainty around Most Favored Nation pricing as a driver of market volatility and measured customer contract durations, while expressing confidence in long-term demand and ROI from AI-enabled marketing solutions.
4. Technical Trends and Analyst Outlook
Shares are trading near 52-week lows and below their 20-day and 100-day SMAs, with RSI at 34.00 and a bullish MACD signal; analysts maintain a Buy consensus with an average target of $23.08 despite recent target cuts.